The DDC gene (Dopa Decarboxylase) encodes aromatic L-amino acid decarboxylase (AADC), also known as DDC. This enzyme is a pyridoxal phosphate (PLP)-dependent decarboxylase that catalyzes the final step in the biosynthesis of the monoamine neurotransmitters dopamine and serotonin. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin[@nagatsu1998][@storch2004].
The DDC gene is essential for normal neurotransmission in both the central and peripheral nervous systems. It is widely used as a marker for dopaminergic and serotonergic neurons due to its enriched expression in these cell populations. Within the brain, DDC is highly expressed in the substantia nigra pars compacta (SNc), ventral tegmental area (VTA), locus coeruleus, and raphe nuclei—regions critical for movement control, reward, arousal, and mood[@boulware2021].
Beyond its fundamental role in neurotransmitter synthesis, DDC has gained significant attention in the context of neurodegenerative diseases. In Parkinson's disease (PD), the efficacy of L-DOPA therapy depends on residual AADC activity in surviving dopaminergic neurons. Furthermore, DDC gene therapy represents a promising approach for restoring dopamine synthesis in patients with advanced PD[@qiu2022][@leWitt2019].
The DDC gene (Dopa Decarboxylase) encodes aromatic L-amino acid decarboxylase (AADC), also known as DDC. This enzyme is a pyridoxal phosphate (PLP)-dependent decarboxylase that catalyzes the final step in the biosynthesis of the monoamine neurotransmitters dopamine and serotonin. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin[@nagatsu1998][@storch2004].
The DDC gene is essential for normal neurotransmission in both the central and peripheral nervous systems. It is widely used as a marker for dopaminergic and serotonergic neurons due to its enriched expression in these cell populations. Within the brain, DDC is highly expressed in the substantia nigra pars compacta (SNc), ventral tegmental area (VTA), locus coeruleus, and raphe nuclei—regions critical for movement control, reward, arousal, and mood[@boulware2021].
Beyond its fundamental role in neurotransmitter synthesis, DDC has gained significant attention in the context of neurodegenerative diseases. In Parkinson's disease (PD), the efficacy of L-DOPA therapy depends on residual AADC activity in surviving dopaminergic neurons. Furthermore, DDC gene therapy represents a promising approach for restoring dopamine synthesis in patients with advanced PD[@qiu2022][@leWitt2019].
Mutations in DDC cause aromatic L-amino acid decarboxylase deficiency (AADCD), a rare autosomal recessive neurotransmitter disorder characterized by early-onset parkinsonism, developmental delay, and autonomic dysfunction[wassenberg2021].
<div class="infobox infobox-gene">
<div class="infobox-header">DDC Gene</div>
<div class="infobox-row">
<div class="infobox-label">Gene Symbol</div>
<div class="infobox-value">DDC</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Aromatic L-amino Acid Decarboxylase</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">7p12.2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/1659" target="_blank">1659</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/608643" target="_blank">608643</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000132437</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value">P20705</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Length</div>
<div class="infobox-value">466 amino acids</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Molecular Weight</div>
<div class="infobox-value">~54 kDa</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal Recessive (AADCD)</div>
</div>
</div>
AADC is a homodimeric enzyme, with each monomer containing the catalytic machinery necessary for decarboxylation. The protein adopts a fold characteristic of the pyridoxal phosphate-dependent decarboxylase family[@boulware2021][@roth2022].
| Domain | Position | Function |
|--------|----------|----------|
| N-terminal domain | 1-150 | Dimerization interface, PLP binding |
| C-terminal domain | 151-466 | Substrate binding, catalytic activity |
The enzyme requires pyridoxal phosphate (PLP, vitamin B6) as an essential cofactor, which forms a Schiff base with an active site lysine residue (Lys303) to form the internal aldimine. Substrate binding leads to transaldimination, forming an external aldimine that undergoes decarboxylation.
AADC employs a ping-pong bi-bi reaction mechanism:
The active site contains critical residues that recognize the catechol ring of L-DOPA, explaining the enzyme's substrate specificity for aromatic amino acids[murphy2018].
AADC catalyzes the final step in the biosynthesis of dopamine and serotonin[@nagatsu1998]:
Dopamine Pathway
Tyrosine → (TH) → L-DOPA → (AADC) → Dopamine
Serotonin Pathway
Tryptophan → (TPH) → 5-HTP → (AADC) → Serotonin
Within dopaminergic neurons, AADC activity determines the efficiency of converting exogenously administered L-DOPA to dopamine. This is critical for PD treatment, as the efficacy of L-DOPA therapy depends on residual AADC activity in surviving nigrostriatal neurons[@lerner2020].
AADC requires pyridoxal phosphate (PLP, vitamin B6) as an essential cofactor:
| Brain Region | Expression Level | Notes |
|--------------|------------------|-------|
| Substantia Nigra (SNc) | Highest | Dopaminergic neurons |
| Ventral Tegmental Area | High | Dopaminergic neurons |
| Locus Coeruleus | High | Noradrenergic neurons |
| Raphe Nuclei | High | Serotonergic neurons |
| Striatum | Moderate | Nerve terminals |
| Cortex | Low-Moderate | Scattered neurons |
| Hippocampus | Low | Interneurons |
DDC is also expressed in peripheral tissues, including adrenal medulla, kidneys, and liver, where it participates in non-neuronal catecholamine synthesis[furness2016].
DDC is central to PD pathophysiology and treatment[@greenmyer2020][@nagatsu2020]:
Endogenous Dopamine Synthesis
DDC activity alterations have been reported in AD:
| Condition | DDC Association |
|-----------|-----------------|
| Multiple System Atrophy (MSA) | AADC activity may be affected in parkinsonian variants |
| Progressive Supranuclear Palsy (PSP) | Altered dopamine metabolism |
| Huntington's Disease | Dysregulated catecholamine synthesis |
| Dementia with Lewy Bodies | AADC deficiency in Lewy body disease |
Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare autosomal recessive neurotransmitter disorder caused by DDC mutations[wassenberg2021][@kojima2020]:
| Feature | Description |
|---------|-------------|
| Onset | Infancy (first year of life) |
| Core symptoms | Infantile-onset parkinsonism, dystonia |
| Motor symptoms | Hypotonia, axial weakness, oculogyric crises |
| Developmental delay | Global delay, severe intellectual disability |
| Autonomic dysfunction | Hypotension, temperature instability |
| Seizures | May occur in some patients |
| Marker | Finding |
|--------|---------|
| CSF L-DOPA | Elevated |
| CSF 5-HTP | Elevated |
| CSF HVA | Low |
| CSF 5-HIAA | Low |
| Plasma AADC activity | Reduced or absent |
| Mutation Type | Severity |
|--------------|----------|
| Null mutations | Severe phenotype |
| Missense mutations | Variable, often milder |
| Pyridoxine-responsive | Some benefit from PLP supplementation |
Pharmacological
DDC Inhibitors
| Drug | Use | Mechanism |
|------|-----|-----------|
| Carbidopa | PD adjunct | Peripheral AADC inhibition |
| Benserazide | PD adjunct | Peripheral AADC inhibition |
Peripheral AADC inhibitors prevent conversion of L-DOPA to dopamine outside the CNS, increasing L-DOPA availability for central conversion. However, they do not affect central AADC activity.
DDC Activators
AAV-mediated DDC gene delivery represents a promising approach for PD[@qiu2022][@leWitt2019]:
Mechanism
DDC/AADC activity serves as a biomarker:
AADC interacts with several proteins in the neurotransmitter synthesis pathway:
| Protein | Function | Interaction |
|---------|----------|-------------|
| TH (Tyrosine Hydroxylase) | Rate-limiting in dopamine synthesis | Downstream of DDC |
| PNMT | Norepinephrine synthesis | Converts dopamine to epinephrine |
| MAOA/B | Dopamine/serotonin catabolism | Downstream metabolism |
| VMAT2 | Monoamine packaging | Packages dopamine into vesicles |
| DAT | Dopamine reuptake | Regulates synaptic dopamine |
| GCH1 | Tetrahydrobiopterin synthesis | Cofactor for TH |
DDC expression and activity change in aging and disease[chen2022]:
| Condition | DDC Change |
|-----------|------------|
| Aging | Decreased AADC activity in SNc |
| PD | Marked reduction in striatum |
| AADCD | Near-absent enzyme activity |
| Depression | Altered in some studies |
Key molecular relationships involving ddc from the SciDEX knowledge graph:
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving DDC Gene discovered through SciDEX knowledge graph analysis: